Login to Your Account

Rekindling Big Pharma’s Interest

Roche Moving Back into Antibiotics Space with $510M Polyphor Deal

By Nuala Moran
Staff Writer

Tuesday, November 5, 2013
LONDON – Polyphor Ltd. is in line for a potential CHF465 million (US$510.6 million) in up-front and milestone payments after outlicensing its antibiotic program POL7080 to Roche AG, in a deal hinting that the various government and regulatory initiatives to promote the development of treatments for drug-resistant infections are rekindling pharma interest in the field.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription